ONO 7122
Alternative Names: ONO-7122Latest Information Update: 25 Aug 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 26 Jun 2023 ONO 7122 licensed to Ono Pharmaceutical in Japan (Ono Pharmaceutical pipeline, June 2023)
- 21 Jun 2023 Phase-I clinical trials in Solid tumours (Combination therapy) in Japan (Parenteral) (Ono pharmaceuticals pipeline, June 2023)
- 31 Jul 2014 Multiple candidates including ONO 7122 licensed to Ono Pharmaceutical in Japan, Taiwan and South Korea